JPWO2020183245A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020183245A5 JPWO2020183245A5 JP2021553382A JP2021553382A JPWO2020183245A5 JP WO2020183245 A5 JPWO2020183245 A5 JP WO2020183245A5 JP 2021553382 A JP2021553382 A JP 2021553382A JP 2021553382 A JP2021553382 A JP 2021553382A JP WO2020183245 A5 JPWO2020183245 A5 JP WO2020183245A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- bispecific antibody
- seq
- isolated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 96
- 102000036639 antigens Human genes 0.000 claims description 96
- 108091007433 antigens Proteins 0.000 claims description 96
- 239000012634 fragment Substances 0.000 claims description 82
- 210000004027 cell Anatomy 0.000 claims description 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 19
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 13
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 230000003013 cytotoxicity Effects 0.000 claims description 4
- 231100000135 cytotoxicity Toxicity 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024135000A JP2024170426A (ja) | 2019-03-11 | 2024-08-13 | 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962816464P | 2019-03-11 | 2019-03-11 | |
| US62/816,464 | 2019-03-11 | ||
| PCT/IB2020/000342 WO2020183245A2 (en) | 2019-03-11 | 2020-03-11 | ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135000A Division JP2024170426A (ja) | 2019-03-11 | 2024-08-13 | 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523442A JP2022523442A (ja) | 2022-04-22 |
| JPWO2020183245A5 true JPWO2020183245A5 (enExample) | 2023-03-17 |
| JP7566766B2 JP7566766B2 (ja) | 2024-10-15 |
Family
ID=71670296
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021553382A Active JP7566766B2 (ja) | 2019-03-11 | 2020-03-11 | 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体 |
| JP2024135000A Pending JP2024170426A (ja) | 2019-03-11 | 2024-08-13 | 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024135000A Pending JP2024170426A (ja) | 2019-03-11 | 2024-08-13 | 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12264197B2 (enExample) |
| EP (1) | EP3937977A2 (enExample) |
| JP (2) | JP7566766B2 (enExample) |
| KR (1) | KR20210138033A (enExample) |
| CN (2) | CN119954959A (enExample) |
| AU (1) | AU2020235475A1 (enExample) |
| BR (1) | BR112021017801A2 (enExample) |
| CA (1) | CA3132916A1 (enExample) |
| IL (1) | IL286147A (enExample) |
| MA (1) | MA55305A (enExample) |
| MX (1) | MX2021010857A (enExample) |
| WO (1) | WO2020183245A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN119954959A (zh) | 2019-03-11 | 2025-05-09 | 詹森生物科技公司 | 抗Vβ17/抗CD123双特异性抗体 |
| JP2023509708A (ja) | 2020-01-03 | 2023-03-09 | マレンゴ・セラピューティクス，インコーポレーテッド | 抗ｔｃｒ抗体分子およびその使用 |
| WO2022035722A1 (en) * | 2020-08-10 | 2022-02-17 | Janssen Biotech, Inc. | Materials and methods for producing bioengineered virus specific lymphocytes |
| US12448449B2 (en) | 2020-09-11 | 2025-10-21 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| UY39416A (es) * | 2020-09-11 | 2022-03-31 | Janssen Biotech Inc | Moléculas de direccionamiento inmunes multiespecíficas y usos de estas |
| KR20230084508A (ko) | 2020-09-11 | 2023-06-13 | 얀센 바이오테크 인코포레이티드 | 베타 사슬 매개 면역을 조절하기 위한 방법 및 조성물 |
| TWI815194B (zh) * | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CN119390841A (zh) * | 2021-11-01 | 2025-02-07 | 詹森生物科技公司 | 用于调节β链介导的免疫的组合物和方法 |
| WO2023152633A1 (en) * | 2022-02-09 | 2023-08-17 | Janssen Biotech, Inc. | Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes |
| CN121127496A (zh) * | 2023-02-09 | 2025-12-12 | 杨森生物技术公司 | 抗Vβ17/抗CD123双特异性抗体 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221352B1 (en) | 1989-03-21 | 2001-04-24 | The Immune Response Corporation | Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells |
| US6413516B1 (en) | 1989-03-21 | 2002-07-02 | The Immune Response Corporation | Peptides and methods against psoriasis |
| FR2681875A1 (fr) | 1991-09-26 | 1993-04-02 | Immunotech Sa | Nouvelles molecules de adn recombinants contenant la partie codante d'une chaine vb17 du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant. |
| US6084087A (en) | 1991-09-27 | 2000-07-04 | New York Society For The Ruptured And Crippled Maintaing The Hospital For Special Surgery | DNA encoding conserved T-cell receptor sequences |
| US6670127B2 (en) | 1997-09-16 | 2003-12-30 | Egea Biosciences, Inc. | Method for assembly of a polynucleotide encoding a target polypeptide |
| DE69830065T2 (de) | 1997-09-16 | 2006-01-19 | Egea Biosciences, LLC, San Diego | Methoden zur kompletten chemischen synthese und zusammensetzung von genen und genomen |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP1594542B1 (en) | 2003-02-20 | 2010-06-30 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer |
| AU2005282700A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| AU2006239860B2 (en) | 2005-04-25 | 2012-01-19 | Amgen Fremont Inc. | Antibodies to myostatin |
| US7585960B2 (en) | 2005-05-11 | 2009-09-08 | Theramab Gmbh | Nucleic acids encoding superagonistic anti-CD28 antibodies |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
| CA2722600C (en) | 2008-05-01 | 2014-01-21 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
| US20110097339A1 (en) | 2008-07-18 | 2011-04-28 | Domantis Limited | Compositions monovalent for CD28 binding and methods of use |
| UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
| EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
| RS56599B1 (sr) | 2010-06-15 | 2018-02-28 | Genmab As | Konjugati humanog antitela sa lekom protiv tkivnog faktora |
| NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
| RU2604490C2 (ru) | 2010-11-05 | 2016-12-10 | Займворкс Инк. | ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ |
| EP2773671B1 (en) | 2011-11-04 | 2021-09-15 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| JP6163502B2 (ja) * | 2012-03-02 | 2017-07-12 | アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ | 抗上皮細胞接着分子（ＥｐＣＡＭ）抗体及びその使用方法 |
| WO2014159531A1 (en) | 2013-03-14 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies targeting epcam for detection of prostate cancer lymph node metastases |
| MX386422B (es) | 2013-12-20 | 2025-03-18 | Fred Hutchinson Cancer Center | Moléculas efectoras químericas etiquetadas y receptores de las mismas. |
| CN107109420A (zh) | 2014-07-21 | 2017-08-29 | 诺华股份有限公司 | 使用cll－1嵌合抗原受体的癌症治疗 |
| JO3568B1 (ar) * | 2014-09-05 | 2020-07-05 | Janssen Pharmaceutica Nv | عوامل ربط cd123 واستخداماتها |
| EP3215538A4 (en) | 2014-11-07 | 2018-07-04 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
| MX381139B (es) | 2015-04-16 | 2025-03-12 | Eisai R&D Man Co Ltd | Anticuerpo anti-notch4 humano. |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| GB201516272D0 (en) | 2015-09-15 | 2015-10-28 | Adaptimmune Ltd And Immunocore Ltd | TCR Libraries |
| CA2997444A1 (en) | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
| TWI790206B (zh) * | 2016-07-18 | 2023-01-21 | 法商賽諾菲公司 | 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白 |
| EP3554515A4 (en) * | 2016-12-15 | 2020-08-26 | Duke University | B10 REGULATORY CELL DEPLETION ANTIBODIES AND METHODS AND THEIR USE IN COMBINATION WITH IMMUNITY CHECKPOINT INHIBITORS |
| US11370830B2 (en) | 2017-04-07 | 2022-06-28 | The Rockefeller University | Neutralizing antibodies that bind to the zika virus domain III envelope region |
| WO2018223002A1 (en) | 2017-06-01 | 2018-12-06 | Xencor, Inc. | Bispecific antibodies that bind cd 123 cd3 |
| WO2019091384A1 (en) | 2017-11-08 | 2019-05-16 | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. | Conjugates of biomolecule and use thereof |
| MX2020014243A (es) | 2018-06-19 | 2021-05-12 | Biontech Us Inc | Neoantigenos y usos de los mismos. |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| AU2020204686A1 (en) | 2019-01-04 | 2021-07-22 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| CN119954959A (zh) | 2019-03-11 | 2025-05-09 | 詹森生物科技公司 | 抗Vβ17/抗CD123双特异性抗体 |
| AU2020298324A1 (en) | 2019-06-21 | 2022-01-27 | Single Cell Technology, Inc. | Anti-TIGIT antibodies |
| BR112022006439A2 (pt) | 2019-10-03 | 2022-07-05 | Janssen Biotech Inc | Métodos para produção de bioterapêuticos com estabilidade aumentada por otimização de sequência |
| KR20220147631A (ko) | 2020-02-27 | 2022-11-03 | 얀센 바이오테크 인코포레이티드 | 면역 반응을 조절하기 위한 물질 및 방법 |
| UY39416A (es) | 2020-09-11 | 2022-03-31 | Janssen Biotech Inc | Moléculas de direccionamiento inmunes multiespecíficas y usos de estas |
| US12448449B2 (en) | 2020-09-11 | 2025-10-21 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| KR20230084508A (ko) | 2020-09-11 | 2023-06-13 | 얀센 바이오테크 인코포레이티드 | 베타 사슬 매개 면역을 조절하기 위한 방법 및 조성물 |
-
2020
- 2020-03-11 CN CN202510015884.6A patent/CN119954959A/zh active Pending
- 2020-03-11 JP JP2021553382A patent/JP7566766B2/ja active Active
- 2020-03-11 KR KR1020217031687A patent/KR20210138033A/ko active Pending
- 2020-03-11 BR BR112021017801A patent/BR112021017801A2/pt unknown
- 2020-03-11 MX MX2021010857A patent/MX2021010857A/es unknown
- 2020-03-11 US US17/437,771 patent/US12264197B2/en active Active
- 2020-03-11 CN CN202080034083.XA patent/CN113874400B/zh active Active
- 2020-03-11 MA MA055305A patent/MA55305A/fr unknown
- 2020-03-11 CA CA3132916A patent/CA3132916A1/en active Pending
- 2020-03-11 EP EP20742831.9A patent/EP3937977A2/en active Pending
- 2020-03-11 AU AU2020235475A patent/AU2020235475A1/en active Pending
- 2020-03-11 WO PCT/IB2020/000342 patent/WO2020183245A2/en not_active Ceased
-
2021
- 2021-09-05 IL IL286147A patent/IL286147A/en unknown
-
2024
- 2024-08-13 JP JP2024135000A patent/JP2024170426A/ja active Pending
-
2025
- 2025-02-24 US US19/061,801 patent/US20250257132A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022177090A5 (enExample) | ||
| JP2024109678A5 (enExample) | ||
| US20230287119A1 (en) | Anti-cd3 antibody and molecules comprising the antibody | |
| CN110294807B (zh) | 抗tim-3抗体 | |
| JP2024038003A5 (enExample) | ||
| JP2020534830A5 (enExample) | ||
| JPWO2020183245A5 (enExample) | ||
| IL277242B2 (en) | Antibodies that bind cd39 and uses thereof | |
| CN115734972A (zh) | 抗cd73抗体及其用途 | |
| CN112135626A (zh) | 抗tigit抗体及其用途 | |
| JP2023093753A5 (enExample) | ||
| JP2021501744A5 (enExample) | ||
| JP2014509835A5 (enExample) | ||
| NZ609619A (en) | Novel egfr-binding molecules and immunoconjugates thereof | |
| JP2013520984A5 (enExample) | ||
| JP2011510654A5 (enExample) | ||
| HRP20130883T4 (hr) | Međuvrsno specifična cd3-epsilon-vežuća domena | |
| JP2020537520A5 (enExample) | ||
| JPWO2019173291A5 (enExample) | ||
| JPWO2019224711A5 (enExample) | ||
| JP2017521054A5 (enExample) | ||
| JP2021512652A5 (enExample) | ||
| CN111712521A (zh) | Cd38蛋白抗体及其应用 | |
| JPWO2023020621A5 (enExample) | ||
| IL277899B2 (en) | Methods and preparations for treating yellow fever |